Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 7/20 | 0.60 |
| ▸ | HTT | P42858 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | USP14 | P54578 | 2/20 | 0.52 |
| ▸ | USP7 | Q93009 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | USP5 | P45974 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921653 | 0.82 | NOTUM (0.60) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL6921657 | 0.81 | NOTUM (0.65) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL6923175 | 0.78 | SMN1; SMN2 (0.64) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL6922827 | 0.77 | NOTUM (0.59) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL6923099 | 0.77 | SMN1; SMN2 (0.65) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL14740398 | 0.75 | NPC1 (1.00) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL6923288 | 0.75 | NOTUM (0.56) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL18452326 | 0.73 | ALDH1A1 (0.71) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL6922311 | 0.71 | NOTUM (0.65) | RAB9ANPC1LMNAHTTTSHR | |
| SCHEMBL21387140 | 0.70 | NOTUM (0.77) | RAB9ANPC1LMNAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145398-B2 | Methods of treating CXCR4-expressing cancers | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785490-B2 | Compounds for treating disease, for administering, and for pharmaceutical compositions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127333-A2 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059852-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | RAB9A 2126/4885NPC1 35/4885LMNA 1347/4885 |
| US-20140303170-A1 | COMPOUNDS FOR TREATING DISEASE, FOR ADMINISTERING, AND FOR PHARMACEUTICAL COMPOSITIONS | PKD1, PCSK9, SLC10A1 | RAB9A 2126/4885NPC1 35/4885LMNA 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.